{
  "source": "PA-Med-Nec-Afstyla.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2123-10\nProgram Prior Authorization/Medical Necessity\nMedication Afstyla® (antihemophilic factor [recombinant], single chain)\nP&T Approval Date 3/2017, 3/2018, 3/2019, 3/2020, 9/2020, 9/2021, 9/2022, 9/2023, 3/2024,\n3/2025\nEffective Date 6/1/2025\n1. Background\nAfstyla (antihemophilic factor [recombinant], single chain) is a recombinant antihemophilic\nfactor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) for:\nOn-demand treatment and control of bleeding episodes\no\nRoutine prophylaxis to reduce the frequency of bleeding episodes\no\nPerioperative management of bleeding\no\nAfstyla is not indicated for the treatment of von Willebrand disease.\n2. Coverage Criteriaa:\nA. Initial Authorization:\n1. Afstyla will be initially approved based on the following criteria:\na. All of the following:\n(1) Diagnosis of hemophilia A\n-AND-\n(2) Patient is not a suitable candidate for treatment with shorter acting half-life Factor\nVIII (recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or\nRecombinate] as attested by the prescriber\n-AND-\n(3) One of the following:\n(a) Patient is not to receive routine infusions more frequently than 3 times per week\n-OR-\n(b) Both of the following:\n1. Patient is less than 12 years of age\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n2. Pharmacokinetic (PK) testing results suggest that more frequent than 3 times\nper week dosing is required\nAuthorization of therapy will be issued for 12 months.\nB. Reauthorization\n1. Afstyla will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Afstyla therapy.\n-AND-\nb. One of the following:\n(1) Patient is not to receive routine infusions more frequently than 3 times per week\n-OR-\n(2) Both of the following:\n(a) Patient is less than 12 years of age\n-AND-\n(b) PK testing results suggest that more frequent than 3 times per week dosing is\nrequired\nAutho",
    "ly than 3 times per week\n-OR-\n(2) Both of the following:\n(a) Patient is less than 12 years of age\n-AND-\n(b) PK testing results suggest that more frequent than 3 times per week dosing is\nrequired\nAuthorization of therapy will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Afstyla® [package insert]. Kankakee, IL: CSL Behring, LLC., June 2023.\n2. Malec L, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis. In:\nUpToDate, Waltham, MA, 2025.\n3. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and\nOther Bleeding Disorders. MASAC Document #290, October 2, 2024.\n© 2025 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Medical Necessity - Afstyla\nChange Control\n3/2017 New program.\n3/2018 Annual review with no changes to coverage criteria.\n3/2019 Annual review with no changes to coverage criteria. Updated reference.\n3/2020 Annual review with no changes to coverage criteria.\n9/2020 Updated preferred standard half-life recombinant products. Updated\nreferences.\n9/2021 Annual review with no changes to coverage criteria. Updated reference.\n9/2022 Annual review. Added text “pharmacokinetic” to clarify abbreviation “PK”\nwith no changes to clinical intent. Updated background per prescribing\ninformation and updated references.\n9/2023 Annual review. Modified physician attestation to prescriber attestation.\nUpdated references.\n3/2024 Annual review with no changes to coverage criteria.\n3/2025 Annual review wi",
    "dated references.\n9/2023 Annual review. Modified physician attestation to prescriber attestation.\nUpdated references.\n3/2024 Annual review with no changes to coverage criteria.\n3/2025 Annual review with no changes to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}